You are here: Industry Insights > Sputnik V

News List

Dr. Reddy’s receives approval to conduct Phase 3 clinical trial for Sputnik V vaccine in India pharmaceutical-business-review
January 20, 2021
Dr. Reddy’s Laboratories has announced that it has received approval from the Drugs Control General of India (DCGI) to conduct phase 3 clinical trial for the Sputnik V vaccine in India.
Dr Reddy’s gets DCGI nod for Phase 3 clinical trial for Sputnik V vaccine expresspharma
January 18, 2021
The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Anvisa sends back request for EUA of Sputnik V vaccine expresspharma
January 18, 2021
Anvisa said that Uniao Quimica, the pharma firm applying for EUA of Sputnik V vaccine, failed to provide adequate assurances on its Phase III clinical trials and issues related to the manufacture of the vaccine.
Dr Reddy’s announces Sputnik V meets primary endpoint of safety in Phase 2 trial in India expresspharma
January 13, 2021
Dr Reddy’s submitted the phase 2 safety data for DCGI’s approval to continue phase 3 clinical trials.
Ukrainian firm applies to make Russia’s COVID-19 vaccine, sparking political dilemma expresspharma
January 07, 2021
Zelenskiy’s government is looking to secure COVID-19 vaccines from China and the global COVAX scheme for poorer nations to fight the pandemic.
Russia approves Sputnik V Covid-19 vaccine for senior citizens pharmaceutical-technology
December 29, 2020
The Russian government has approved its Covid-19 vaccine, Sputnik V, for use by individuals aged 60 years and above.
Argentina registers Russia’s Covid-19 vaccine Sputnik V pharmaceutical-technology
December 25, 2020
The Russian Direct Investment Fund (RDIF) has announced that the National Administration of Drugs, Foods and Medical Devices of Argentina (ANMAT) has registered the Sputnik V vaccine against Covid-19.
Volunteers in Russia’s Sputnik V vaccine trials will no longer receive placebos – RIA expresspharma
December 24, 2020
Moscow’s Gamaleya Institute, the developer of the first Russian vaccine against COVID-19, said on Wednesday that volunteers in its large-scale final-stage trials for the Sputnik V shot will no longer receive placebos, RIA news agency reported.
India to make 300 million Sputnik V vaccines expresspharma
December 21, 2020
India will produce about 300 million doses of Russia’s Sputnik V coronavirus vaccines next year, a Russian official was quoted as saying, nearly three times the previously known number as deals have been signed with more manufacturers.
Russian says its ‘Sputnik V’ COVID-19 vaccine is 92% effective pharmatimes
November 12, 2020
A COVID-19 vaccine developed by the Gamaleya Center in Russia is 92% effective, the Russian Direct Investment Fund (RDIF) said yesterday.

Previous page 1 2 3 4 5 6 7 8 Next page